Urinary excretion of cyclic adenosine monophosphate (cAMP) is assessed in response to pitressin stimulation in three patients with nephrogenic diabetes insipidus, four carriers and seven controls. There is no significant difference in cAMP excretion between these groups when corrected for surface area, nor is there any significant increase in excretion after pitressin stimulation. There is very close correlation between urinary cAMP and both urinary concentration and urinary creatinine excretion. Urinary cAMP after pitressin stimulation does not discriminate between carriers of nephrogenic diabetes insipidus and control subjects.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Bell, N. H., Clark, C. M., Avery, S., Sinha, T., Trygstad, C. and Allan, D. D. (1972). Demonstration of defects in the formation of and response to cyclic adenosine 3′,5′-monophosphate in vasopressin-resistant diabetes insipidus.Clin. Res.,20, 586
Bell, N. H., Clark, C. M., Avery, S., Sinha, T., Trygstad, C. and Allen, D. D. (1974). Demonstration of a defect in the formation of adenosine 3′,5′-monophosphate in vasopressin-resistant diabetes insipidus.Pediatr. Res.,8, 223
Broadus, A. E., Kaminsky, N. I., Hardman, J. G., Sutherland, E. W. and Liddle, G. W. (1970). Kinetic parameters and renal clearances of plasma adenosine 3′,5′-monophosphate and guanosine 3′,5′-monophosphate in man.J. Clin. Invest.,49, 2222
Brown, B. L., Ekins, R. E. and Albano, J. D. M. (1972). Saturation assay for cyclic AMP using endogenous binding protein.Adv. Cyclic Nucleotide Res.,2, 25
Carter, C. and Simpkiss, M. (1956). The ‘carrier’ state in nephrogenic diabetes insipidus.Lancet,ii, 1069
Chase, L. R. and Aurbach, G. D. (1968). Renal adenyl cyclase; anatomically separate sites for parathyroid hormone and vaso-pressin.Science,159, 545
Chase, L. R., Melson, G. L. and Aurbach, G. D. (1969). Pseudohypothyroidism: defective excretion of 3′,5′-AMP in response to parathyroid hormone.J. Clin. Invest.,48, 1832
Fichman, M. P. and Brooker, G. (1972). Deficient renal cyclic adenosine 3′,5′-monophosphate production in nephrogenic diabetes insipidus.J. Clin. Endocrinol.,35, 35
Hardman, J. G. (1971). Cyclic GMP and cyclic AMP in urine. In:Cyclic AMP. New York and London: Academic Press
Jones, N. F., Barraclough, M. A., Barnes, N. and Cottom, D. G. (1972). Nephrogenic diabetes insipidus. Effects of 3,5-cyclic-adenosine monophosphate.Arch. Dis. Child.,47, 794
Orloff, J. and Handler, J. (1962). The similarity of effects of vasopressin adenosine 3′,5′-phosphate (cyclic AMP) and theophylline on the toad bladder.J. Clin. Invest.,41, 702
Orloff, J. and Handler, J. (1967). The role of adenosine 3′,5′-phosphate in the action of antidiuretic hormone.Am. J. Med.,42, 757
Porter, G. M. (1974). Investigation of some clinical applications of urinary cyclic AMP determinations. PhD Thesis, University of Edinburgh
Raij, K., Perheentupa, J. and Harkonen, M. (1974). Urinary cyclic adenosine monophosphate excretion in diabetes insipidus of childhood.Scand. J. Clin. Lab. Invest.,34, 177
Royer, P. (1974). The hereditary tubular diseases. In:Paediatric Nephrology (P. Royer, R. Habib, H. Mathieu and M. Broyer, eds.; A. Walsh, transl.). Philadelphia, London and Toronto: W. B. Saunders Co.
Uttley, W. S. and Thistlethwaite, D. (1972). Failure to detect the carrier in congenital nephrogenic diabetes insipidus.Arch. Dis. Child.,47, 137
About this article
Cite this article
Uttley, W.S., Atkinson, B., Adams, A. et al. Cyclic adenosine monophosphate excretion in urine of patients and carriers of congenital nephrogenic diabetes insipidus. J Inherit Metab Dis 1, 75–77 (1978). https://doi.org/10.1007/BF01801849
- Control Subject
- Metabolic Disease